Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Itron, Inc.

ITRI
Technology · Scientific & Technical Instruments

Itron, Inc. is cheap for a reason. The P/E sits at the 24th percentile of its own range, and the quarters are still getting worse.

The sharpest disagreement: annual EPS moved +25.5% against a −13.7% price move — the market has not yet caught up with the delivery.

The price is topping out (2 weeks in) while the P/E sits at the 24th percentile of its own 3-year range. Underneath, the last four quarters read deteriorating — profit −28.6% year on year, and 120% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
$106
−13.7% 1Y
P/E
17.7×
24th pctile
of its own 3-year range
Revenue (Mar 26)
$0.6 B
−3.3% YoY
Profit (Mar 26)
$0.1 B
−28.6% YoY
Operating margin
11.9%
−1.2 pp YoY
ROE
17%
FY25
ROIC
10.3%
vs WACC 8.9% → +1.4 pp
Cash conversion
120%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Itron, Inc. trades at $106, losing momentum at the top and 2 weeks into that stage. That is +12.7% against its own 200-day average. It sits at 48% of a 52-week range of $79 to $136. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.

Today the stock is losing momentum at the top — week 2 of stage 3. At $106 it trades +12.7% versus its 200-day average and sits at 48% of its 52-week range ($79–$136).

Aug 26: $106 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+12.7% versus the 200-day line, week 2 of stage 3
Price50-day avg200-day avg
S2S2S1S4$143$120$96.8$73.8$50.8$$106$94Jul 23Apr 24Jan 25Oct 25Aug 26
S2S2S1S4$143$120$96.8$73.8$50.8$$106$94Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +147% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Itron, Inc. trades at 17.7× P/E, near the bottom of its own range — cheaper only 24% of the time. Its long-run median P/E is 22.6×, measured across 3.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 17.7× is near the bottom of its own range — cheaper only 24% of the time, against a long-run median of 22.6× measured over 3.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

P/E 17.7× vs a 22.6× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 3.1-year window; loss-period spikes above 68× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 24% of the time
P/EMedianEPS (TTM) (quarterly)
72.1×$7.056.1×$5.340.2×$3.524.2×$1.88.2×$0.0×$16.95×$6Jun 23Apr 24Jan 25Oct 25Aug 26
72.1×$7.056.1×$5.340.2×$3.524.2×$1.88.2×$0.0×$16.95×$6Jun 23Jan 25Aug 26
PEG 0.77 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
3.5×2.8×2.0×1.2×0.4××0.77×Sep 21Sep 22Dec 23Mar 25Jun 26
3.5×2.8×2.0×1.2×0.4××0.77×Sep 21Dec 23Jun 26
P/E
17.7×
24th percentile of 3y
PEG
0.91
as reported

Why the multiple sits where it does: over the past year annual EPS moved +25.5% against a −13.7% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the +14.0%/yr price move, ~+94.7%/yr came from earnings growth and ~−80.7 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Itron, Inc. reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +350.0% at its peak to +11.5% but is still expanding, ROCE holding at 10.5%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue −2.9% in FY25, profit +25.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
23%155%14%120%5.8%85%−2.9%50%−11%15%%%−2.9%25%FY21FY23FY25
23%155%14%120%5.8%85%−2.9%50%−11%15%%%−2.9%25%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over, profit rolling over
RevenueProfitEPS
28%323%20%239%11%156%2.2%72%−6.5%−12%%%−4.1%11.5%14.4%Jun 23Sep 24Mar 26
28%323%20%239%11%156%2.2%72%−6.5%−12%%%−4.1%11.5%14.4%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
12%9.8%7.1%4.5%1.9%%10.5%Jun 23Dec 23Sep 24Jun 25Mar 26
12%9.8%7.1%4.5%1.9%%10.5%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest −4.1% · span −4.1% to +26.0%
Profit growth
Rolling over
latest +11.5% · span +11.5% to +350.0%
EPS growth
Rolling over
latest +14.4% · span +13.9% to +376.5%
ROCE
Stuck low
latest 10.5% · span 2.6%–11.7%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue−2.9%+9.6%
Profit+25.0%
EPS+25.5%
Stock price−13.7%+14.0%+6.6%+9.4%
Revenue YoY (Mar 26)
−3.3%
latest quarter vs a year ago
Profit YoY (Mar 26)
−28.6%
latest quarter vs a year ago
Revenue 10y
4.6%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

44.2/100 — rank 14 of 19 in Scientific & Technical Instruments · 56% evidence confidence

Itron, Inc. scores 44.2 out of 100 against the 19 companies it is compared with in Scientific & Technical Instruments, ranking 14. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 14.6 + 9.8 + 11.1 + 8.7 = 44.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Itron, Inc. reported $0.6 B of revenue in the Mar 26 quarter, −3.3% year on year. Over 4 years it has compounded at 4.6% a year. The last full year, FY25, came in at $2.4 B. The last four reported quarters add to $2.3 B.

FY25 revenue came in at $2.4 B (−2.9% on the year), capping 4 years at 4.6% compound. The latest quarter (Mar 26) printed $0.6 B, −3.3% year on year.

FY25 revenue $2.4 B (−2.9% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.6% a year over 4 years
RevenueYoY growth
2.623%2.014%1.35.8%0.7−2.9%0.0−11%$ B%$2B−2.9%FY21FY23FY25
2.623%2.014%1.35.8%0.7−2.9%0.0−11%$ B%$2B−2.9%FY21FY23FY25
Mar 26: $0.6 B (−3.3% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.736%0.525%0.313%0.21.8%0.0−9.8%$ B%$1B−3.3%Jun 23Sep 24Mar 26
0.736%0.525%0.313%0.21.8%0.0−9.8%$ B%$1B−3.3%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged −4.1% growth against the decade's 4.6% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew −4.1% over the last 4 quarters against +1.5%/yr over the last 8 — rolling over; TTM profit +11.5% vs +34.6%/yr — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Itron, Inc.'s operating margin is 11.9% in the Mar 26 quarter, −1.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −4.0% to 13.1%. The current quarter sits inside that band.

The latest quarter's operating margin is 11.9%, −1.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.0%–13.1%, and FY25's 13.1% is the top of that band — a record year.

🚨 Why the margin moved: operating margin went −1.2 pp year on year while gross margin went +4.6 pp — the loss came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 13.1% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a −4.0–13.1% band over 5 years
operating marginYoY change (pp)
14%6.9%9.5%5.7%4.6%4.5%−0.4%3.3%−5.4%2.1%%%13.1%2.4%FY21FY23FY25
14%6.9%9.5%5.7%4.6%4.5%−0.4%3.3%−5.4%2.1%%%13.1%2.4%FY21FY23FY25
Mar 26: 11.9% operating margin (−1.2 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
15%16%13%11%11%6.6%8.8%2.1%6.9%−2.4%%%11.9%−1.2%Jun 23Sep 24Mar 26
15%16%13%11%11%6.6%8.8%2.1%6.9%−2.4%%%11.9%−1.2%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Itron, Inc. earned $0.1 B of net profit in the Mar 26 quarter, −28.6% year on year. Full-year FY25 profit was $0.3 B. That is 8.5% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.

Mar 26 profit was $0.1 B, −28.6% year on year. On the full year, FY25 printed $0.3 B (+25.0%).

FY25 profit $0.3 B (+25.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.3149%0.2116%0.183%0.049%−0.116%$ B%$0B25%FY21FY23FY25
0.3149%0.2116%0.183%0.049%−0.116%$ B%$0B25%FY21FY23FY25
Mar 26: $0.1 B (−28.6% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.11110%0.0873%0.0536%0.03−1.6%0.00−39%$ B%$0B−28.6%Jun 23Sep 24Mar 26
0.11110%0.0873%0.0536%0.03−1.6%0.00−39%$ B%$0B−28.6%Jun 23Sep 24Mar 26

🚨 Why profit moved: revenue contributed −3.3% and the margin −1.2 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +16.4% vs revenue −4.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 120% of Itron, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.4 B of operating cash against $0.3 B of profit. After $0.0 B of capital spending, $0.4 B was left as free cash.

FY25: operating cash of $0.4 B against reported profit of $0.3 B, leaving free cash of $0.4 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 120% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.4 B vs profit $0.3 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
120% of 3-year profit arrived as cash
Operating cashNet profitFree cash
0.40.30.20.0−0.1$ B$0B$0B$0BFY21FY23FY25
0.40.30.20.0−0.1$ B$0B$0B$0BFY21FY23FY25
Jun 26: operating cash $0.1 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.13188%0.10158%0.06128%0.0397%0.0067%$ B%$0B180%Sep 23Dec 24Jun 26
0.13188%0.10158%0.06128%0.0397%0.0067%$ B%$0B180%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Itron, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.0320.0240.0160.0080.000$ B$0BFY21FY23FY25
0.0320.0240.0160.0080.000$ B$0BFY21FY23FY25
Jun 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0110.120.0080.090.0050.070.0030.050.0000.02$ B$ B$0B$0BSep 23Dec 24Jun 26
0.0110.120.0080.090.0050.070.0030.050.0000.02$ B$ B$0B$0BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Itron, Inc. earns a ROE of 17% in FY25. That is up from a trough of −7% in FY21. Return on invested capital clears the cost of that capital by +1.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.7% net margin on 0.64× asset turns.

FY25 ROE is 17%, recovered from a FY21 trough of −7% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 12.7% net margin × 0.64× asset turns × 2.14× balance-sheet leverage ≈ 17.4% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 10.3% − 8.9% = a +1.4 pp spread. The 8.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 17% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 8.9% cost of capital used on this page.
the climb back from FY21's −7%
ROEROIC (annual)WACC
19%12%5.1%−1.9%−8.9%%17.2%15.4%FY21FY23FY25
19%12%5.1%−1.9%−8.9%%17.2%15.4%FY21FY23FY25
Jun 26: ROIC 13.2% (TTM) vs WACC 8.9% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
21%17%13%8.5%4.2%%13.2%17.5%Sep 23Dec 24Jun 26
21%17%13%8.5%4.2%%13.2%17.5%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Itron, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Itron, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Itron, Inc. carries total debt of $1.6 B against shareholder equity of $1.6 B as of Jun 26, a debt-to-equity of 0.98. On the annual view that ratio went from 0.45 in FY21 to 0.73 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $1.6 B against shareholder equity of $1.6 B — a debt-to-equity of 0.98. On the annual view, debt-to-equity went from 0.45 (FY21) to 0.73 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $1.3 B at 0.73× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
1.40.9×1.00.8×0.70.6×0.30.5×0.00.3×$ B×$1B0.73×FY21FY23FY25
1.40.9×1.00.8×0.70.6×0.30.5×0.00.3×$ B×$1B0.73×FY21FY23FY25
Jun 26: debt $1.6 B, debt-to-equity 0.98 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.71.1×1.30.9×0.90.7×0.40.5×0.00.3×$ B×$2B0.98×Sep 23Dec 24Jun 26
1.71.1×1.30.9×0.90.7×0.40.5×0.00.3×$ B×$2B0.98×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

14.2% of Itron, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 9.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 14.2% of the float is sold short, and at typical trading volumes it would take about 9.5 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
14.2%
of the tradable float
Days to cover
9.5
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Itron, Inc.: the Z-score reads 2.40. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.40 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.40.

15 · Related companies · Scientific & Technical Instruments
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Keysight Technologies, Inc.KEYS 67.2/100Favorable setup81% evidence ASLEEP 28.4/35 Revenue 19.2% · PAT 44.6% · OPM change 7.9 pp 83% evidence 15.0/25 ROCE 4.5% · OPM 23.7% 76% evidence 11.3/20 P/E 57.6× · PEG 1.35 65% evidence 12.5/20 RS sector 14.9% · RS bench 22.7% · 1Y 106.9%4 of 12 weeks ahead 100% evidence
Exact sum: 28.4 + 15 + 11.3 + 12.5 = 67.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Garmin Ltd.GRMN 66.3/100Thin evidence · provisional56% evidence TURNING 21.3/35 Revenue — · PAT — · OPM change 2.9 pp 39% evidence 17.0/25 ROCE 6.9% · OPM 24.6% 76% evidence 10.8/20 P/E 24× · PEG — 15% evidence 17.2/20 RS sector 9.7% · RS bench 18.7% · 1Y 32.3%2 of 12 weeks ahead 100% evidence
Exact sum: 21.3 + 17 + 10.8 + 17.2 = 66.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Cognex CorporationCGNX 59.9/100Thin evidence · provisional56% evidence FADING 22.3/35 Revenue — · PAT — · OPM change 4.9 pp 39% evidence 14.9/25 ROCE 3.4% · OPM 22.3% 76% evidence 9.4/20 P/E 58.5× · PEG — 15% evidence 13.3/20 RS sector 19.6% · RS bench 28.4% · 1Y 74.8%11 of 12 weeks ahead 100% evidence
Exact sum: 22.3 + 14.9 + 9.4 + 13.3 = 59.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4MKS Inc.MKSI 56.4/100Mixed-positive evidence66% evidence FADING 19.6/35 Revenue 11.5% · PAT 43.4% · OPM change 1.9 pp 53% evidence 10.2/25 ROCE 2.1% · OPM 13.8% 57% evidence 12.8/20 P/E 48.1× · PEG 1.13 65% evidence 13.8/20 RS sector 22.9% · RS bench 30.5% · 1Y 222.8%10 of 12 weeks ahead 100% evidence
Exact sum: 19.6 + 10.2 + 12.8 + 13.8 = 56.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Novanta Inc.NOVT 54.3/100Thin evidence · provisional56% evidence BREAKING OUT 21.4/35 Revenue — · PAT — · OPM change 4.5 pp 39% evidence 9.8/25 ROCE 2% · OPM 10.7% 76% evidence 8.9/20 P/E 84.8× · PEG — 15% evidence 14.2/20 RS sector 2.8% · RS bench 10.9% · 1Y 37.9%10 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 9.8 + 8.9 + 14.2 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
6Ituran Location and Control Ltd.ITRN 53.1/100Thin evidence · provisional60% evidence ASLEEP 15.8/35 Revenue 11.3% · PAT 6.9% · OPM change -0.1 pp 53% evidence 15.9/25 ROCE 8.6% · OPM 21.5% 57% evidence 10.5/20 P/E 16.2× · PEG 1.8 65% evidence 10.9/20 RS sector -0.1% · RS bench 7.3% · 1Y 34.1%6 of 12 weeks ahead 70% evidence
Exact sum: 15.8 + 15.9 + 10.5 + 10.9 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Coherent Corp.COHR 52.4/100Thin evidence · provisional56% evidence ASLEEP 23.2/35 Revenue 18% · PAT 100% · OPM change 6.3 pp 53% evidence 7.7/25 ROCE 1.4% · OPM 11.1% 57% evidence 8.5/20 P/E 114× · PEG — 15% evidence 13.0/20 RS sector 21.8% · RS bench 29.1% · 1Y 180.4%7 of 12 weeks ahead 100% evidence
Exact sum: 23.2 + 7.7 + 8.5 + 13 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Teledyne Technologies IncorporatedTDY 51.3/100Thin evidence · provisional56% evidence TURNING 17.8/35 Revenue — · PAT — · OPM change 1 pp 39% evidence 13.0/25 ROCE 2.5% · OPM 18.9% 76% evidence 10.6/20 P/E 30.1× · PEG — 15% evidence 9.9/20 RS sector -3.9% · RS bench 3.8% · 1Y 25.4%1 of 12 weeks ahead 100% evidence
Exact sum: 17.8 + 13 + 10.6 + 9.9 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Sensata Technologies Holding plcST 50.7/100Thin evidence · provisional56% evidence FADING 18.2/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence 11.0/25 ROCE 2.7% · OPM 15.1% 76% evidence 9.0/20 P/E 79.6× · PEG — 15% evidence 12.5/20 RS sector 8.6% · RS bench 16.8% · 1Y 65.2%11 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 11 + 9 + 12.5 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Vontier CorporationVNT 49.3/100Thin evidence · provisional56% evidence TURNING 16.1/35 Revenue — · PAT — · OPM change 0.4 pp 39% evidence 14.7/25 ROCE 3.6% · OPM 18% 76% evidence 11.3/20 P/E 12.5× · PEG — 15% evidence 7.2/20 RS sector -24.2% · RS bench -17.3% · 1Y -16.6%1 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 14.7 + 11.3 + 7.2 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11ESCO Technologies Inc.ESE 47.0/100Mixed-negative evidence66% evidence TURNING 17.7/35 Revenue 30.7% · PAT 16.7% · OPM change -0.5 pp 53% evidence 13.1/25 ROCE 2.8% · OPM 15.5% 57% evidence 4.7/20 P/E 54.2× · PEG 6 65% evidence 11.5/20 RS sector 6.9% · RS bench 14.8% · 1Y 68.8%3 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 13.1 + 4.7 + 11.5 = 47 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Trimble Inc.TRMB 46.2/100Thin evidence · provisional56% evidence BASING 20.2/35 Revenue — · PAT — · OPM change 3.7 pp 39% evidence 10.5/25 ROCE 1.9% · OPM 15.3% 76% evidence 10.4/20 P/E 33.1× · PEG — 15% evidence 5.1/20 RS sector -29.8% · RS bench -23.1% · 1Y -28.6%0 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 10.5 + 10.4 + 5.1 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Badger Meter, Inc.BMI 46.2/100Thin evidence · provisional56% evidence TURNING 13.7/35 Revenue — · PAT — · OPM change -4.8 pp 39% evidence 15.4/25 ROCE 4.8% · OPM 17.4% 76% evidence 10.1/20 P/E 34.7× · PEG — 15% evidence 7.0/20 RS sector -27.5% · RS bench -20.6% · 1Y -25.5%3 of 12 weeks ahead 100% evidence
Exact sum: 13.7 + 15.4 + 10.1 + 7 = 46.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Itron, Inc.this pageITRI 44.2/100Thin evidence · provisional56% evidence TURNING 14.6/35 Revenue — · PAT — · OPM change -1.1 pp 39% evidence 9.8/25 ROCE 2.5% · OPM 11.5% 76% evidence 11.1/20 P/E 14.4× · PEG — 15% evidence 8.7/20 RS sector -12.4% · RS bench -4.2% · 1Y -15.3%2 of 12 weeks ahead 100% evidence
Exact sum: 14.6 + 9.8 + 11.1 + 8.7 = 44.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15Vishay Precision Group, Inc.VPG 42.5/100Thin evidence · provisional56% evidence LEADER 13.3/35 Revenue — · PAT — · OPM change -3.2 pp 39% evidence 4.5/25 ROCE 0.1% · OPM 0.4% 76% evidence 8.7/20 P/E 99.5× · PEG — 15% evidence 16.0/20 RS sector 48.6% · RS bench 56.9% · 1Y 271.3%12 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 4.5 + 8.7 + 16 = 42.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Fortive CorporationFTV 41.5/100Thin evidence · provisional53% evidence ASLEEP 15.8/35 Revenue — · PAT — · OPM change -5.6 pp 32% evidence 8.6/25 ROCE 1.7% · OPM 9% 76% evidence 10.3/20 P/E 33.3× · PEG — 15% evidence 6.8/20 RS sector -9.3% · RS bench -1.9% · 1Y 28.5%0 of 12 weeks ahead 100% evidence
Exact sum: 15.8 + 8.6 + 10.3 + 6.8 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Mesa Laboratories, Inc.MLAB 39.8/100Thin evidence · provisional51% evidence ASLEEP 16.1/35 Revenue 3.7% · PAT — · OPM change 1.9 pp 40% evidence 6.3/25 ROCE 0.9% · OPM 4.3% 57% evidence 9.2/20 P/E 73.1× · PEG — 15% evidence 8.2/20 RS sector -1.5% · RS bench 6% · 1Y 57.3%4 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 6.3 + 9.2 + 8.2 = 39.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18USBC, Inc.USBC 43.4/100Thin evidence · provisional20% evidence ASLEEP 17.3/35 Revenue — · PAT — · OPM change — 2% evidence 11.1/25 ROCE — · OPM — 11% evidence 11.5/20 P/E 0.9× · PEG — 15% evidence 3.5/20 RS sector -54% · RS bench -48.9% · 1Y -84.2%0 of 12 weeks ahead 70% evidence
Exact sum: 17.3 + 11.1 + 11.5 + 3.5 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19MicroVision, Inc.MVIS 30.4/100Thin evidence · provisional39% evidence 10.6/35 Revenue -80% · PAT — · OPM change -129 pp 40% evidence 6.8/25 ROCE -35.2% · OPM — 46% evidence 10.0/20 P/E — · PEG — 0% evidence 3.0/20 RS sector -68.3% · RS bench -66.3% · 1Y -76.9%0 of 10 weeks ahead 70% evidence
Exact sum: 10.6 + 6.8 + 10 + 3 = 30.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Itron, Inc.'s stock price today?

Itron, Inc. trades at $106, −13.7% over the past year. The company is valued at $5.0 B. The stock sits at 48% of its 52-week range of $79–$136, +12.7% versus its 200-day average. On the tape, the price is topping out, 2 weeks in. — as of 5 August 2026.

What were Itron, Inc.'s latest quarterly results?

Itron, Inc. reported revenue of $0.6 B and net profit of $0.1 B for the Mar 26 quarter. Revenue fell 3.3% and profit fell 28.6% year on year. Earnings per share were $1.18. The operating margin was 11.9%, 1.2 pp lower than a year earlier. — as of 5 August 2026.

What is Itron, Inc.'s revenue?

Itron, Inc. reported revenue of $0.6 B in the Mar 26 quarter, −3.3% year on year. For the full FY25 fiscal year, revenue was $2.4 B (−2.9%). Over the last 4 years revenue compounded at 4.6% a year. — as of 5 August 2026.

What is Itron, Inc.'s profit?

Itron, Inc. earned $0.1 B of net profit in the Mar 26 quarter, −28.6% year on year. Full-year FY25 profit was $0.3 B. The operating margin ran 11.9% in the latest quarter. — as of 5 August 2026.

What is Itron, Inc.'s market cap?

Itron, Inc.'s market capitalisation is $5.0 B at a stock price of $106. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

What is Itron, Inc.'s P/E ratio?

Itron, Inc. trades at a P/E of 17.7×, at the 24th percentile of its own 3-year range, against a long-run median of 22.6×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.

Does Itron, Inc. pay a dividend?

No — Itron, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

Is Itron, Inc. overvalued?

On its own history, Itron, Inc. looks cheap against its own history: its P/E of 17.7× has been cheaper only 24% of the time in 3 years (long-run median 22.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 5 August 2026.

Is Itron, Inc. growing?

Not right now — Itron, Inc.'s latest numbers are shrinking: latest-quarter revenue −3.3% year on year, profit −28.6%, and the margin −1.2 pp at 11.9%. The earnings engine currently reads: deteriorating — as of 5 August 2026.

How is Itron, Inc. performing?

Itron, Inc. is topping out, 2 weeks in. Its latest quarter's revenue fell 3.3% and profit fell 28.6% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Itron, Inc. in?

Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +350.0% at its peak to +11.5% but is still expanding, ROCE holding at 10.5%. The read comes from the last 12 quarters of growth (revenue growth −4.1% latest, profit growth +11.5% latest, eps growth +14.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Itron, Inc. in an uptrend?

It is stalling — the price is topping out (week 2 of stage 3), trading +12.7% versus its 200-day average and at 48% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Itron, Inc. beating the market?

On recent form, yes — Itron, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +147% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will Itron, Inc.'s stock price go up?

This page publishes no price forecast for Itron, Inc. What it measures instead: the stock price is $106, the price is topping out 2 weeks in. Its P/E of 17.7× sits at the 24th percentile of its own 3-year range. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Itron, Inc.?

Yes — short interest is 14.2% of Itron, Inc.'s tradable float, about 9.5 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Itron, Inc. have too much debt?

It is moderate — Itron, Inc.'s debt-to-equity is 0.98. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is Itron, Inc.'s capex?

Itron, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.

What is Itron, Inc.'s cash flow?

Itron, Inc. generated $0.4 B of operating cash flow in FY25 and $0.4 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Itron, Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 120% of Itron, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.4 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Itron, Inc.?

On the balance sheet, the Z-score reads 2.40 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.

Where is Itron, Inc. in its business cycle?

Itron, Inc.'s FY25 operating margin was 13.1%, against a 5-year band of −4.0%–13.1%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 11.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Itron, Inc. story?

The sharpest disagreement: annual EPS moved +25.5% against a −13.7% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Itron, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Itron, Inc. is cheap for a reason. The P/E sits at the 24th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI